Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 2
2006 3
2007 7
2008 7
2009 6
2010 10
2011 13
2012 9
2013 15
2014 18
2015 20
2016 21
2017 13
2018 12
2019 9
2020 9
2021 14
2022 13
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

190 results

Results by year

Filters applied: . Clear all
Page 1
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
Peyrin-Biroulet L, Allegretti JR, Rubin DT, Bressler B, Germinaro M, Huang KG, Shipitofsky N, Zhang H, Wilson R, Han C, Feagan BG, Sandborn WJ, Panés J, Hisamatsu T, Lichtenstein GR, Sands BE, Dignass A; QUASAR Study Group. Peyrin-Biroulet L, et al. Gastroenterology. 2023 Dec;165(6):1443-1457. doi: 10.1053/j.gastro.2023.08.038. Epub 2023 Sep 1. Gastroenterology. 2023. PMID: 37659673 Free article. Clinical Trial.
Efficacy and safety of 1 L polyethylene glycol plus ascorbic acid for bowel preparation in elderly: comparison with oral sulfate solution.
Lim KY, Kim KO, Kim EY, Lee YJ, Jang BI, Kim SK, Yang CH; Crohn’s and Colitis Association in Daegu-Gyeongbuk (CCAiD). Lim KY, et al. Among authors: jang bi. Korean J Intern Med. 2023 Sep;38(5):651-660. doi: 10.3904/kjim.2023.030. Epub 2023 Jul 24. Korean J Intern Med. 2023. PMID: 37482653 Free PMC article. Clinical Trial.
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
D'Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, Krueger K, Laskowski J, Li X, Lissoos T, Milata J, Morris N, Arora V, Milch C, Sandborn W, Sands BE; LUCENT Study Group. D'Haens G, et al. N Engl J Med. 2023 Jun 29;388(26):2444-2455. doi: 10.1056/NEJMoa2207940. N Engl J Med. 2023. PMID: 37379135 Clinical Trial.
Incidence of colonoscopy-related perforation and risk factors for poor outcomes: 3-year results from a prospective, multicenter registry (with videos).
Lee J, Lee YJ, Seo JW, Kim ES, Kim SK, Jung MK, Heo J, Lee HS, Lee JS, Jang BI, Kim KO, Cho KB, Kim EY, Kim DJ, Chung YJ; Daegu-Gyeongbuk Gastrointestinal Study Group. Lee J, et al. Among authors: jang bi. Surg Endosc. 2023 Aug;37(8):5865-5874. doi: 10.1007/s00464-023-10046-5. Epub 2023 Apr 17. Surg Endosc. 2023. PMID: 37069430
Endoscopist-Driven Sedation Practices in South Korea: Re-evaluation Considering the Nationwide Survey in 2019.
Park SY, Lee JK, Park CH, Kim BW, Lee CK, Park HJ, Jang BI, Kim DU, Park JM, Lee JM, Cho YS, Chon HK, Seo SY, Paik WH; Committees of Quality Management and Conscious Sedation of Korean Society of Gastrointestinal Endoscopy (KSGE). Park SY, et al. Among authors: jang bi. Gut Liver. 2022 Nov 15;16(6):899-906. doi: 10.5009/gnl210466. Epub 2022 Aug 1. Gut Liver. 2022. PMID: 35912649 Free PMC article.
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, Greenspan A, Allez M, Danese S, Hanauer SB, Jairath V, Kuehbacher T, Lewis JD, Loftus EV Jr, Mihaly E, Panaccione R, Scherl E, Shchukina OB, Sandborn WJ; SEAVUE Study Group. Sands BE, et al. Lancet. 2022 Jun 11;399(10342):2200-2211. doi: 10.1016/S0140-6736(22)00688-2. Lancet. 2022. PMID: 35691323 Clinical Trial.
190 results